CADTH

pan-Canadian Pharmaceutical Alliance (pCPA): July 2019 Trends and Insights   The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the status of brand negotiations as of July 31, 2019. Highlights since the last update include: 5 products completed CADTH review, for a total of 12 files under consideration; 7 products initiated pCPA negotiations, for a total of 47 active negotiations; 6 negotiations completed for a total of 263 completed negotiations; 3 negotiations…

pan-Canadian Pharmaceutical Alliance (pCPA): June 2019 Trends and Insights   The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the status of brand negotiations as of June 30, 2019. Highlights since the last update include: 6 products completed CADTH review, for a total of 15 files under consideration; 9 products initiated pCPA negotiations, for a total of 49 active negotiations; 4 negotiations completed for a total of 257 completed negotiations; 3 negotiations…

On November 27, 2018 the BC Ministry of Health changed coverage of glatiramer products, GLATECT™ and COPAXONE®, which demonstrates a shift from previous public drug plan approaches for funding of subsequent entry products (biosimilars) for chronic diseases.   Background   GLATECT™ is the first subsequent entry glatiramer-based treatment available for reimbursement for RRMS in Canada – i.e. a follow on product to Copaxone®. It is classifed as a non-biological complex…

Summary of Expensive Drugs for Rare Diseases (EDRD) Working Group Webinar   Signals Decoded:   Stakeholder consultation is underway on a supplemental process for complex/specialized drugs that builds upon the existing national HTA and reimbursement process to make responsive funding decisions with a focus on non-oncology therapies. The supplemental process is a significant development in EDRD policy and it looks to streamline the evaluation and reimbursement process of eligible drugs…

Panel 6: Presidents’ Roundtable   Panel Description: This session brought together general managers from three innovative pharmaceutical companies operating in Canada to explore their insights on how the current reimbursement environment is impacting their company, its decision-making and patient access. Moderator: Barbara Jaszewski Panelists: Peter Brenders, Brian Canestraro and Ben Faienza Barbara Jaszewski: CAHR 201 has been a great way to get a fast introduction to all the changes that…

Summary of CADTH Drug Portfolio Information Session   Date: Thursday, November 1, 2018 Time: 1:30 pm to 4:00 pm Presenters: Brian O’Rourke, Brent Fraser, Alex Chambers, Trevor Richter, Heather Logan, Tarry Ahuja, Michelle Mujoomdar, Harindra Wijeysundera Purpose: An opportunity for all interested stakeholders to get the latest information about priority initiatives and process changes from CADTH’s pharmaceutical reviews portfolio, including the CADTH Common Drug Review (CDR), the CADTH pan-Canadian Oncology…

CAPT Conference Workshop: Defining “Decision Grade” Real World Evidence (RWE) and its Role in the Canadian Context: A Design Sprint   On Sunday October 21, 2018, the Canadian Association of Population Therapeutics (CAPT) hosted a full day workshop to discuss recent advances in the dialogue on RWE in Canada from a Regulatory, HTA and Reimbursement perspective. The day was attended by participants invited from various stakeholder groups including Health Canada,…

Panel 3: Health Technology Assessment   Panel Description: Canada’s centralized HTA agency, CADTH, has recently released a new 3-year strategic plan that marks a shift from its previous vision. Noteworthy is the focus of recommendations on alignment of drug assessment with the priorities of the participating plans over all phases of the technology life cycle. Join us to hear CADTH describe their new strategic plan, how their mandate has evolved,…

Aligned Reviews Between Health Canada (HC) and Health Technology Assessment Organizations (HTAs)   Date: September 26th, 2018 Time: 10:00 AM - 11:30 AM Presenters: Alex Chambers (CADTH), Virginie Landreville (INESSS), M Coyer (HC), and T Richter (CADTH) Purpose: To describe the HC-HTA (CADTH and INESSS) aligned review process in more detail, and discuss any questions regarding this initiative. This initiative aims to improve regulatory review in order to obtain more…

Panel 2: Pharmacoeconomics   Panel Description: This panel will focus on the growing influence of pharmacoeconomics (PE) in the Canadian reimbursement process. It will discuss the implications of the revised CADTH PE guidelines on CDR and pCODR reviews. The panellists will also discuss the implications of using PE thresholds for price regulations. In addition, the impact of PE models on pCPA negotiations will also be explored. Moderator: Chris Cameron Panellists:…

On September 13th, 2018, the Canadian Agency for Drugs and Technologies in Health (CADTH) issued details on a new CADTH and Institut national d’excellence en santé et en services sociaux (INESSS) pilot project to jointly engage with clinical specialists. According to CADTH’s communication, the objectives of the pilot project are to: Strengthen the current pharmaceutical review processes used by CADTH and INESSS with respect to engagement with Canadian clinical specialists.…

A Comparison of Proposed INESSS and Current CADTH Evaluation Fees   On February 21, 2018, the Quebec government released draft regulations (Gazette Officielle du Québec) that outline fees payable to Institut national d'excellence en santé et en services sociaux (INESSS) for the scientific evaluation of a drug or stable blood product. The fees are expected to vary based on the type of dossier submitted for scientific review with INESSS determining…